{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T04:47:59Z","timestamp":1791607679363,"version":"4.3.4"},"reference-count":14,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2013,3,7]],"date-time":"2013-03-07T00:00:00Z","timestamp":1362614400000},"content-version":"vor","delay-in-days":310,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["The Journal of Clinical Pharma"],"published-print":{"date-parts":[[2012,5]]},"abstract":"<jats:p>Although contraindicated, coingestion of alcohol and opioids by patients or drug abusers is a major health concern because of dangerous additive and potentially life\u2010threatening sedative and respiratory effects. In addition, alcohol has been shown to disrupt the extended\u2010release characteristics of certain extended\u2010release opioid formulations, releasing a hazardous amount of opioid over a short time period. Morphine sulfate and naltrexone hydrochloride extended release capsules (MS\u2010sNT), which contain naltrexone sequestered in each pellet core, are indicated for management of chronic, moderate to severe pain. Sequestered naltrexone is designed for release upon product tampering (crushing) to potentially mitigate morphine\u2010induced subjective effects. This open\u2010label, single\u2010dose, 4\u2010way crossover, pharmacokinetic drug interaction study compared the relative bioavailability of morphine and naltrexone when MS\u2010sNT is administered (under fasting conditions) with increasing doses of alcohol. Thirty\u2010two healthy, opioid\u2010naive adults were randomized to MS\u2010sNT administered with 240 mL of 4%, 20%, or 40% alcohol or water. No drug interaction was found between morphine in MS\u2010sNT and 4% or 20% alcohol. Administration with 40% alcohol did not affect overall morphine exposure but was associated with a 2\u2010fold increase in C<jats:sub>max<\/jats:sub> and reduction of t<jats:sub>max<\/jats:sub> from 9 to 4 hours versus MS\u2010sNT taken with water. Naltrexone sequestering was successful in all treatment arms and not affected by coadministration with alcohol over the dose range tested.<\/jats:p>","DOI":"10.1177\/0091270011403740","type":"journal-article","created":{"date-parts":[[2011,5,19]],"date-time":"2011-05-19T03:56:30Z","timestamp":1305777390000},"page":"747-756","source":"Crossref","is-referenced-by-count":25,"title":["Effects of Alcohol on the Pharmacokinetics of Morphine Sulfate and Naltrexone Hydrochloride Extended Release Capsules"],"prefix":"10.1002","volume":"52","author":[{"given":"Franklin K.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Ciric","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Boudriau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Kisicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Stauffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,3,7]]},"reference":[{"key":"e_1_2_5_2_2","volume-title":"Results From the 2007 National Survey on Drug Use and Health: National Findings","author":"Substance Abuse and Mental Health Services Administration","year":"2008"},{"key":"e_1_2_5_3_2","volume-title":"Drug Abuse Warning Network, 2006: National Estimates of Drug\u2010Related Emergency Department Visits","author":"Substance Abuse and Mental Health Services Administration","year":"2008"},{"key":"e_1_2_5_4_2","first-page":"40","article-title":"Alcohol and medication interactions","volume":"23","author":"Weathermon R","year":"1999","journal-title":"Alcohol Res Health"},{"key":"e_1_2_5_5_2","unstructured":"US Food and Drug Administration.Alert for Healthcare Professionals: Hydromorphone Hydrochloride Extended\u2010Release Capsules(marketed as Palladone).July 2005.http:www.fda.govDrugsDrugSafetyPostmarketDrugSafetyInformationforPatientsandProvidersucm129288.htm. Accessed August 20 2009."},{"key":"e_1_2_5_6_2","volume-title":"Avinza [package insert]","year":"2008"},{"key":"e_1_2_5_7_2","volume-title":"package insert","author":"Opana ER","year":"2008"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2008.01.162"},{"key":"e_1_2_5_9_2","volume-title":"Embeda [package insert]","year":"2009"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpain.2007.11.009"},{"key":"e_1_2_5_11_2","volume-title":"In Vivo Drug Metabolism\/Drug Interaction Studies\u2010Study Design, Data Analysis, and Recommendations for Dosing and Labeling","author":"US Food and Drug Administration","year":"1999"},{"key":"e_1_2_5_12_2","volume-title":"Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products\u2014General Considerations","author":"US Food and Drug Administration","year":"2003"},{"key":"e_1_2_5_13_2","first-page":"132","volume-title":"Narcotic Antagonists: Naltrexone Pharmaco\u2010chemistry and Sustained\u2010Release Preparations","author":"Misra AL","year":"1981"},{"issue":"4","key":"e_1_2_5_14_2","doi-asserted-by":"crossref","first-page":"P35","DOI":"10.1016\/j.jpain.2008.01.157","article-title":"Relative bioavailability of plasma naltrexone from crushed ALO\u201001 (an investigational, abuse\u2010deterrent, extended\u2010release, morphine sulfate formulation with sequestered naltrexone) to a naltrexone oral solution [abstract 236]","volume":"9","author":"Johnson F","year":"2008","journal-title":"J Pain"},{"key":"e_1_2_5_15_2","unstructured":"JohnsonFK CiricS BoudriauS SwearingenD StaufferJ.Effect of food and sprinkling of pellets on applesauce on the pharmacokinetics of ALO\u201001. Abstract presented at: American Association of Pharmaceutical Scientists (AAPS) November 20 16\u20132008; Atlanta GA."}],"container-title":["The Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1177%2F0091270011403740","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/0091270011403740","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T14:54:03Z","timestamp":1698677643000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1177\/0091270011403740"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5]]},"references-count":14,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012,5]]}},"alternative-id":["10.1177\/0091270011403740"],"URL":"https:\/\/doi.org\/10.1177\/0091270011403740","archive":["Portico"],"relation":{},"ISSN":["0091-2700","1552-4604"],"issn-type":[{"value":"0091-2700","type":"print"},{"value":"1552-4604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5]]}}}